All In Biotech

NDA 208216 · Actavis LLC

Azacitidine

Azacitidine · Intravenous, Subcutaneous · Nucleoside Metabolic Inhibitor

Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 29, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,227

154 Phase 3, 243 recruiting

FAERS reports

18,638

18,081 serious, 6,121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 26, 2025.

Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL) ( 1 ). 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for Injection is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Pediatric use information is approved for Celgene Corporation’s Vidaza ® (azacitidine for injection). However due to Celgene Corporation’s marketing exclusivity rights, this drug product is not labeled with that information.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • AZACITIDINE · AZACITIDINE 100MG/VIAL · POWDER, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Azacitidine" as an intervention, any sponsor and status, largest first.

All 1,227 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia2,057
  • death1,880
  • myelosuppression1,698
  • off label use1,620
  • neutropenia1,457
  • acute myeloid leukaemia1,318
  • pneumonia1,084
  • thrombocytopenia1,069
  • pyrexia1,034
  • drug ineffective1,026
  • anaemia885
  • infection705

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20053
20061
20075
200816
200943
201086
2011119
201291
201378
2014278
2015404
2016322
2017670
2018754
2019942
20201,161
20211,981
20222,609
20232,465
20242,347
20252,559
20261,703

Recalls

1 FDA enforcement reports for this application.

  • Jul 22, 2022 · Class III · Terminated

    Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 16, 2026

    Azacitidine, Injection, 100 mg (NDC 68001-313-56). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azacitidine (Azacitidine)

2024 spending

$3.1M

Beneficiaries

304

1,662 claims

Per beneficiary

$10,056

$185.60 per unit

View as table
YearSpending
2020$2,344,665
2021$2,064,383
2022$4,576,309
2023$3,717,671
2024$3,057,055

Part B: Azacitidine* (Azacitidine*) · HCPCS J9025

2024 spending

$6.1M

Beneficiaries

3,474

91,156 claims

Per beneficiary

$1,765

2024 ASP limit $0.38 per unit

View as table
YearSpending
2020$40,293,093
2021$33,142,126
2022$26,546,456
2023$7,273,322
2024$6,132,117

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 431 on PubMed

Sponsor: Actavis LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.